EF Hutton analyst Chip Moore reiterates Amprius Technologies (NYSE:AMPX) with a Buy and maintains $14 price target.
AlloVir’s RSV Therapy Is Underappreciated Gem, BofA Comments On Future Potential
B of A Securities analyst Jason Zemansky initiated coverage on AlloVir Inc (NASDAQ: ALVR) with a Buy rating and